KEY POINTS
  • Johnson & Johnson said its shareholders will soon be able to swap their shares for stock of Kenvue, which spun out as an independent consumer health company just two months ago.
  • J&J owns nearly 90% of Kenvue shares and plans to reduce its stake through an exchange offer that could launch "as early as the coming days," J&J CFO Joseph Wolk said during an earnings call. 
  • Both companies reported second-quarter earnings that beat Wall Street's expectations.

In this article

Thibaut Mongon, CEO and Paul Ruh CFO of Kenvue Inc. a Johnson & Johnson's consumer-health business, pose together during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023.

Johnson & Johnson on Thursday said its shareholders will soon be able to swap their shares for stock of Kenvue, which spun out as an independent consumer health company just two months ago.

J&J owns nearly 90% of Kenvue shares and plans to reduce its stake through an exchange offer that could launch "as early as the coming days," depending on market conditions, J&J CFO Joseph Wolk said during the company's second-quarter earnings call. 

In this article